SCHEMBL4144891

SCHEMBL4144891

CN(C)CCNc1ccc(-c2nc3c(C(=O)NC4CCCCC4)ccnc3[nH]2)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 1/20 0.42
UHRF1 Q96T88 1/20 0.42
PBK Q96KB5 3/20 0.41
ACVR1 Q04771 1/20 0.41
RAB9A P51151 1/20 0.37
CNR1 P21554 4/20 0.37
CNR2 P34972 3/20 0.37
CD38 P28907 2/20 0.37
HSD11B1 P28845 1/20 0.37
ROCK2 O75116 1/20 0.37
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36
LMNA P02545 1/20 0.36
GLA P06280 1/20 0.36
MAPK1 P28482 1/20 0.36
AXL P30530 1/20 0.36
PTGES O14684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4153517 0.90 PBK (0.47) RAD52UHRF1PBKACVR1
SCHEMBL4162695 0.88 ACVR1 (0.42) RAD52UHRF1PBKACVR1CNR1
SCHEMBL13778218 0.87 CNR1 (0.40) RAD52UHRF1PBKACVR1CNR1
SCHEMBL13778203 0.85 ALDH1A1 (0.40) RAD52UHRF1PBKCNR2KDM4E
SCHEMBL13778206 0.85 ALDH1A1 (0.40) RAD52UHRF1PBKCNR2KDM4E
SCHEMBL4159072 0.85 TDP1 (0.41) RAD52UHRF1PBKKDM4EALDH1A1
SCHEMBL4152141 0.83 NPC1 (0.48) PBKRAB9ACNR1CNR2
SCHEMBL4152581 0.83 NPC1 (0.48) PBKRAB9ACNR1CNR2
SCHEMBL4961738 0.83 RAD52 (0.43) RAD52UHRF1RAB9AKDM4E
SCHEMBL4152290 0.83 RAD52 (0.44) RAD52UHRF1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP claimed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 RAD52 4618/4885UHRF1 3834/4885PBK 999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.